Indoco Remedies launches FEVINDO : 400 mg Favipiravir


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ indoco-remedies-launches-favipiravir-fevindo-400-mg
Now Indoco joins Favipiravir production with 400mg tablets

(Favipiravir) 400 mg Tablets in India. Fevindo - 400 (Favipiravir) is an antiviral drug, effective against the RNA-based influenza virus. The drug has been approved by DCGI in the treatment of Covid-19. Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.

Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. commented, “The Covid-19 crisis has created a vast disruption to life in India and all over the globe. As part of the pharma industry, we have been able to do our bit in the prevention of Covid-19 with our brands Karvol Plus, ATM, Febrex Plus and Rexidin SRS Mouthwash. With the launch of FEVINDO, we are taking the next step from prevention to the treatment of Covid-19.”

Fevindo - 400 (Favipiravir) will be made available at all government approved COVID care centres and selected medical practitioners across the country. In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D. Indoco has always been committed to providing quality medicines at affordable prices and with the launch of these products, the Company is all set to venture into the treatment of Covid-19.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialities.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal,

Tags : #IndocoRemedies #FavipiravirLaunch #IndocoFavipiravir #FevindoFavipiravir #latestFavipiravirNewsSep28 #latestPharmaNewsSep28

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

The Value of Risk Communication in Public HealthOctober 08, 2026
What Makes a Reliable Health Screening Programme?October 08, 2026
How Language Access Can Improve Patient Communication in Indian HealthcareOctober 07, 2026
Why Health Literacy Matters in Preventive HealthcareOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
How Community Health Workers Support Preventive Care DeliveryOctober 07, 2026
AI in India's Emergency Departments: Reducing Diagnostic DelaysOctober 06, 2026
AI and Patient Consent in India: Who Is Responsible?October 06, 2026
Wearable Technology in Pregnancy: Benefits and LimitsOctober 06, 2026
Remote Monitoring for High-Risk Pregnancies in IndiaOctober 06, 2026
Fortis Escorts Faridabad Launches ‘Sehat Express’ Mobile Bus for Accessible Doorstep Cancer Screening in association with Faridabad Industries Association Charitable Society and Rotary Club FaridabadOctober 05, 2026
Advanced Thrombectomy Saves 60-Year-Old Woman After Severe Heart Attack at KIMS SaveeraOctober 05, 2026
Constipation, Bloating and Long Sitting Hours: Doctors at RG Hospitals Delhi Warn Urban Professionals Not to Ignore Gut ProblemsOctober 05, 2026
Fermenta – Centre of Excellence for Food Fortification Inaugurated at NIFTEM-T, ThanjavurOctober 05, 2026
Alzheimer’s Dementia: Recognising the Signs, Diagnosing Earlier and Changing the Future of Brain HealthOctober 05, 2026
Man Matters Hairfall Case Study 2026: 7 Lakh+ Consultations Reveal How Hair Loss Changes With AgeOctober 05, 2026
Medication Reconciliation: A System-Level Step for Safer Transitions of CareOctober 05, 2026
The Role of Clinical Pharmacists in Safer Medication UseOctober 05, 2026
Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026